NorthStar Medical Radioisotopes Signs Contract with IBA for Eight Rhodotron Electron Beam Accelerators to Expand US Production of Non-uranium Based Radioisotope Mo-99.
M2 PHARMA-April 2, 2019-NorthStar Medical Radioisotopes Signs Contract with IBA for Eight Rhodotron Electron Beam Accelerators to Expand US Production of Non-uranium Based Radioisotope Mo-99
(C)2019 M2 COMMUNICATIONS
- US-based nuclear medicine technology company NorthStar Medical Radioisotopes, LLC and IBA (Ion Beam Applications S.A., EURONEXT), a provider of proton therapy solutions for the treatment of cancer, have signed a contract with NorthStar for the purchase of as many as eight Rhodotron TT300 HE electron beam accelerators from IBA, the companies said.
NorthStar has issued purchase orders for the two initial units and intends to order the remaining units in coming years.
The RadioGenix System is an innovative, high tech separation platform that is approved for processing non-uranium/non-highly enriched uranium based molybdenum-99 (Mo-99) for the production of the important medical radioisotope, technetium-99m (Tc-99m).
Prior to availability of RadioGenix technology, the US supply chain for Mo-99 has been subject to frequent and sometimes severe interruptions which negatively impact patient healthcare.
Approved by the US Food and Drug Administration in February 2018, the RadioGenix System is the first and only on-site, automated isotope separation system of its kind for use with non-uranium/non-highly enriched uranium based Mo-99.
Indication and Important Risk Information About the RadioGenix System and Sodium Pertechnetate Tc 99m Injection USP
The RadioGenix System is a technetium Tc-99m generator used to produce Sodium Pertechnetate Tc 99m Injection, USP. Sodium Pertechnetate Tc 99m Injection is a radioactive diagnostic agent and can be used in the preparation of FDA-approved diagnostic radiopharmaceuticals.
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer.
IBA Industrial is part of the Other Accelerators division of IBA (Ion Beam Application S.A.). IBA Industrial develops, installs and maintains solutions for customers in a wide range of markets and applications, including (but not exclusive to) Medical Device sterilization in E-beam and X-ray. These applications are supported by two types of accelerators, the Dynamitron and the Rhodotron.
NorthStar Medical Radioisotopes is a nuclear medicine technology company. The company's first product is the RadioGenix System, an innovative and flexible platform technology initially approved by the US Food and Drug Administration in February 2018 for the processing of non-uranium/non-highly enriched uranium based molybdenum-99 (Mo-99), the parent isotope of technetium-99m (Tc-99m), which is currently the most widely used diagnostic radioisotope for medical purposes.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Date:||Apr 2, 2019|
|Previous Article:||Celgene Receives CHMP Positive Opinions for Both Revlimid and Imnovid-Based Triplet Combination Regimens for Patients with Multiple Myeloma.|
|Next Article:||Data Published in The Lancet Shows that CT-P13 is Non-inferior to Reference Infliximab in Inflammatory Bowel Disease.|